Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies.

Kusawake T, Kowalski D, Takada A, Kato K, Katashima M, Keirns JJ, Lewand M, Lasseter KC, Marbury TC, Preston RA.

Adv Ther. 2017 Dec;34(12):2612-2624. doi: 10.1007/s12325-017-0643-3. Epub 2017 Nov 13.

2.

Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies.

Kusawake T, Keirns JJ, Kowalski D, den Adel M, Groenendaal-van de Meent D, Takada A, Ohtsu Y, Katashima M.

Adv Ther. 2017 Dec;34(12):2625-2637. doi: 10.1007/s12325-017-0642-4. Epub 2017 Nov 13.

3.

Reproducibility of QTc interval changes after meal intake.

Hnatkova K, Kowalski D, Keirns JJ, van Gelderen EM, Malik M.

J Electrocardiol. 2015 Mar-Apr;48(2):194-202. doi: 10.1016/j.jelectrocard.2015.01.006. Epub 2015 Jan 8.

PMID:
25601409
4.

Are QTc interval changes after meal intake a reasonable method to prove assay sensitivity in thorough QT studies?

Hnatkova K, Kowalski D, Keirns JJ, van Gelderen EM, Malik M.

J Electrocardiol. 2015 Mar-Apr;48(2):276-7. doi: 10.1016/j.jelectrocard.2015.01.005. Epub 2015 Jan 6. No abstract available.

PMID:
25578392
5.

QTc changes after meal intake: sex differences and correlates.

Hnatkova K, Kowalski D, Keirns JJ, van Gelderen EM, Malik M.

J Electrocardiol. 2014 Nov-Dec;47(6):856-62. doi: 10.1016/j.jelectrocard.2014.07.026. Epub 2014 Aug 2.

PMID:
25173631
6.

ICH E14-compatible holter bin method and its equivalence to individual heart rate correction in the assessment of drug-induced QT changes.

Malik M, Hnatkova K, Kowalski D, Keirns JJ, Van Gelderen EM.

J Cardiovasc Electrophysiol. 2014 Nov;25(11):1232-41. doi: 10.1111/jce.12450. Epub 2014 Jun 11.

PMID:
24801246
7.

Have individual QT/RR curvatures value in QT correction?

Malik M, Hnatkova K, Kowalski D, Keirns JJ, van Gelderen EM.

J Electrocardiol. 2014 May-Jun;47(3):386-91. doi: 10.1016/j.jelectrocard.2014.01.010. Epub 2014 Jan 31. No abstract available.

PMID:
24698409
8.

Assessment of tacrolimus absorption from the human intestinal tract: open-label, randomized, 4-way crossover study.

Tsunashima D, Kawamura A, Murakami M, Sawamoto T, Undre N, Brown M, Groenewoud A, Keirns JJ, Holman J, Connor A, Wylde H, Wilding I, Ogawara K, Sako K, Higaki K, First R.

Clin Ther. 2014 May;36(5):748-59. doi: 10.1016/j.clinthera.2014.02.021. Epub 2014 Mar 27.

PMID:
24680768
9.

QT/RR curvatures in healthy subjects: sex differences and covariates.

Malik M, Hnatkova K, Kowalski D, Keirns JJ, van Gelderen EM.

Am J Physiol Heart Circ Physiol. 2013 Dec;305(12):H1798-806. doi: 10.1152/ajpheart.00577.2013. Epub 2013 Oct 25.

10.

Relationship of QT interval variability to heart rate and RR interval variability.

Hnatkova K, Kowalski D, Keirns JJ, van Gelderen EM, Malik M.

J Electrocardiol. 2013 Nov-Dec;46(6):591-6. doi: 10.1016/j.jelectrocard.2013.07.007. Epub 2013 Aug 9.

PMID:
23938108
11.

Pharmacokinetics of intravenous conivaptan in subjects with hepatic or renal impairment.

Roy MJ, Erdman KA, Abeyratne AT, Plumb LC, Lasseter K, Riff DS, Keirns JJ.

Clin Pharmacokinet. 2013 May;52(5):385-95. doi: 10.1007/s40262-013-0047-8.

PMID:
23456393
12.

Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study.

Malik M, van Gelderen EM, Lee JH, Kowalski DL, Yen M, Goldwater R, Mujais SK, Schaddelee MP, de Koning P, Kaibara A, Moy SS, Keirns JJ.

Clin Pharmacol Ther. 2012 Dec;92(6):696-706. doi: 10.1038/clpt.2012.181. Epub 2012 Nov 14.

PMID:
23149929
13.

Importance of subject-specific QT/RR curvatures in the design of individual heart rate corrections of the QT interval.

Malik M, Hnatkova K, Kowalski D, Keirns JJ, van Gelderen EM.

J Electrocardiol. 2012 Nov-Dec;45(6):571-81. doi: 10.1016/j.jelectrocard.2012.07.017. Epub 2012 Sep 20.

PMID:
22999325
14.

Population pharmacokinetic-pharmacodynamic analysis of vernakalant hydrochloride injection (RSD1235) in atrial fibrillation or atrial flutter.

Mao Z, Wheeler JJ, Townsend R, Gao Y, Kshirsagar S, Keirns JJ.

J Pharmacokinet Pharmacodyn. 2011 Oct;38(5):541-62. doi: 10.1007/s10928-011-9207-3. Epub 2011 Jul 24.

PMID:
21786177
15.

The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates.

Hope WW, Mickiene D, Petraitis V, Petraitiene R, Kelaher AM, Hughes JE, Cotton MP, Bacher J, Keirns JJ, Buell D, Heresi G, Benjamin DK Jr, Groll AH, Drusano GL, Walsh TJ.

J Infect Dis. 2008 Jan 1;197(1):163-71. doi: 10.1086/524063.

16.

Population pharmacokinetics of micafungin in adult patients.

Gumbo T, Hiemenz J, Ma L, Keirns JJ, Buell DN, Drusano GL.

Diagn Microbiol Infect Dis. 2008 Mar;60(3):329-31. Epub 2007 Nov 19.

PMID:
18024052
17.

Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing.

Hope WW, Seibel NL, Schwartz CL, Arrieta A, Flynn P, Shad A, Albano E, Keirns JJ, Buell DN, Gumbo T, Drusano GL, Walsh TJ.

Antimicrob Agents Chemother. 2007 Oct;51(10):3714-9. Epub 2007 Jul 16.

18.

The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants.

Heresi GP, Gerstmann DR, Reed MD, van den Anker JN, Blumer JL, Kovanda L, Keirns JJ, Buell DN, Kearns GL.

Pediatr Infect Dis J. 2006 Dec;25(12):1110-5.

PMID:
17133155
19.

Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450.

Erickson DA, Mather G, Trager WF, Levy RH, Keirns JJ.

Drug Metab Dispos. 1999 Dec;27(12):1488-95.

PMID:
10570031
20.

Biotransformation of nevirapine, a non-nucleoside HIV-1 reverse transcriptase inhibitor, in mice, rats, rabbits, dogs, monkeys, and chimpanzees.

Riska PS, Joseph DP, Dinallo RM, Davidson WC, Keirns JJ, Hattox SE.

Drug Metab Dispos. 1999 Dec;27(12):1434-47.

PMID:
10570025
21.

Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor.

Hauss DJ, Fogal SE, Ficorilli JV, Price CA, Roy T, Jayaraj AA, Keirns JJ.

J Pharm Sci. 1998 Feb;87(2):164-9.

PMID:
9519148
22.

Pharmacokinetics of nevirapine: initial single-rising-dose study in humans.

Cheeseman SH, Hattox SE, McLaughlin MM, Koup RA, Andrews C, Bova CA, Pav JW, Roy T, Sullivan JL, Keirns JJ.

Antimicrob Agents Chemother. 1993 Feb;37(2):178-82.

23.

Biologic activity of purified cotton bract extracts in man and guinea pig.

Buck MG, Schachter EN, Fick RB, Merrill WW, Cooper JA Jr, Keirns JJ, Oliver J, Wall JH.

Environ Health Perspect. 1986 Apr;66:37-44.

24.

Relative bioavailability of chlorthalidone in humans after single oral doses.

Farina PR, MacGregor TR, Horhota ST, Keirns JJ.

J Pharm Sci. 1985 Sep;74(9):995-8.

PMID:
4067856
25.

Pharmacokinetics of transdermally delivered clonidine.

MacGregor TR, Matzek KM, Keirns JJ, van Wayjen RG, van den Ende A, van Tol RG.

Clin Pharmacol Ther. 1985 Sep;38(3):278-84.

PMID:
4028622
26.

Chlorthalidone pharmacodynamics in beagle dogs.

MacGregor TR, Keirns JJ, Farina PR, Matzek KM, Horhota ST, Esber HJ.

J Pharm Sci. 1985 Aug;74(8):851-6.

PMID:
4032269
27.

Radioimmunoassay for clonidine in human plasma and urine using a solid phase second antibody separation.

Farina PR, Homon CA, Chow CT, Keirns JJ, Zavorskas PA, Esber HJ.

Ther Drug Monit. 1985;7(3):344-50.

PMID:
4049475
28.

Pharmacokinetics of oral sustained release clonidine in humans.

MacGregor TR, Relihan GL, Keirns JJ.

Arzneimittelforschung. 1985;35(1A):440-6.

PMID:
4039184
29.

Analysis of chlorthalidone in biological fluids by high-performance liquid chromatography using a rapid column cleanup procedure.

MacGregor TR, Farina PR, Hagopian M, Hay N, Esber HJ, Keirns JJ.

Ther Drug Monit. 1984;6(1):83-90.

PMID:
6710559
30.

Isolation and characterization of metaproterenol-3-O-sulfate: a conjugate of metaproterenol in human urine.

MacGregor TR, Nastasi L, Farina PR, Keirns JJ.

Drug Metab Dispos. 1983 Nov-Dec;11(6):568-73.

PMID:
6140141
31.

Purification and properties of the light-activated cyclic nucleotide phosphodiesterase of rod outer segments.

Miki N, Baraban JM, Keirns JJ, Boyce JJ, Bitensky MW.

J Biol Chem. 1975 Aug 25;250(16):6320-7.

32.

The amphibian melanocyte: microtubules, cyclic AMP, and organelle translocation.

Bitensky MW, Keirns CN, Keirns JJ.

Ann N Y Acad Sci. 1975 Jun 30;253:685-91. Review. No abstract available.

PMID:
167639
33.
34.

Preparation of isolated epididymal capillary endothelial cells and their use in the study of cyclic AMP metabolism.

Keirns JJ, Wagner RC, Bitensky MW.

Methods Enzymol. 1975;39:479-82. No abstract available.

PMID:
168473
35.

Activation of photoreceptor disk membrane phosphodiesterase by light and ATP.

Bitensky MW, Miki N, Keirns JJ, Keirns M, Baraban JM, Freeman J, Wheeler MA, Lacy J, Marcus FR.

Adv Cyclic Nucleotide Res. 1975;5:213-40. No abstract available.

PMID:
165667
36.
37.

Cyclic adenosine monophosphate and clinical medicine. 2. Carbohydrate and lipid metabolism.

Keirns JJ, Freeman J, Bitensky MW.

Am J Med Sci. 1974 Aug;268(2):62-91. No abstract available.

PMID:
4153310
38.

Proceedings: Light regulation of adenosine 3',5' cyclic monophosphate levels in vertebrate photoreceptors.

Miki N, Keirns JJ, Marcus FR, Bitensky MW.

Exp Eye Res. 1974 Mar;18(3):281-97. No abstract available.

PMID:
4366186
39.
40.

The role of cyclic nucleotides in visual excitation.

Bitensky MW, Miki N, Marcus FR, Keirns JJ.

Life Sci. 1973 Dec 1;13(11):1451-72. Review. No abstract available.

PMID:
4361595
41.

Regulation of cyclic nucleotide concentrations in photoreceptors: an ATP-dependent stimulation of cyclic nucleotide phosphodiesterase by light.

Miki N, Keirns JJ, Marcus FR, Freeman J, Bitensky MW.

Proc Natl Acad Sci U S A. 1973 Dec;70(12):3820-4.

42.

Hormonal control of melanocytes: MSH-sensitive adenyl cyclase in the Cloudman melanoma.

Kreiner PW, Gold CJ, Keirns JJ, Brock WA, Bitensky MW.

Yale J Biol Med. 1973 Dec;46(5):583-91. No abstract available.

43.

Cyclic adenosine monophosphate and clinical medicine. I.

Bitensky MW, Keirns JJ, Freeman J.

Am J Med Sci. 1973 Nov;266(5):321-47. Review. No abstract available.

PMID:
4361536
44.

Adenosine 3',5' cyclic monophosphate in Euglena gracilis.

Keirns JJ, Carritt B, Freeman J, Eisenstadt JM, Bitensky MW.

Life Sci. 1973 Aug 16;13(4):287-302. No abstract available.

PMID:
4356580
45.

A temperature-sensitive change in the energy of activation of hormone-stimulated hepatic adenylyl cyclase.

Kreiner PW, Keirns JJ, Bitensky MW.

Proc Natl Acad Sci U S A. 1973 Jun;70(6):1785-9.

46.

An abrupt temperature-dependent change in the energy of activation of hormone-stimulated hepatic adenylyl cyclase.

Keirns JJ, Kreiner PW, Bitensky MW.

J Supramol Struct. 1973;1(4):368-79. No abstract available.

PMID:
4767465
47.

Studies on nicotinamide adenine dinucleotide phosphate reductase of spinach chloroplasts.

Keirns JJ, Wang JH.

J Biol Chem. 1972 Nov 25;247(22):7374-82. No abstract available.

48.

The subunit structure of beef heart cytochrome oxidase.

Keirns JJ, Yang CS, Gilmour MV.

Biochem Biophys Res Commun. 1971 Nov;45(4):835-41. No abstract available.

PMID:
4330142

Supplemental Content

Loading ...
Support Center